"There'd be just less competition," says Tom Harrington, a TV analyst from Enders. "The ability there would be to charge a bit more."
但这种垄断格局，即将被打破，多款在研新药正从作用机制到给药方式，向Vosoritide发起挑战。Ascendis的TransCon-CNP通过包裹技术延长了药物作用时间，实现了周剂给药，目前正处于FDA审批阶段；而BridgeBio的口服药Infigratinib，则从作用机制到用药体验实现全面突破。，详情可参考一键获取谷歌浏览器下载
。谷歌浏览器【最新下载地址】对此有专业解读
news.flinders.edu.au。业内人士推荐heLLoword翻译官方下载作为进阶阅读
As bats lose their habitats, churches are becoming a refuge for the animals